EXS-21546
Exscientia
['check,mate,056', 'nsclc', 'sclc', 'ca,022,i', 'ca,022,1', 'ca,022,001', 'renal,(-adrenal)', 'translational,medicine', 'ignite', 'biomarker', 'rcc,(-irccs),(-srcc),(-urcc)', 'selection,(-selectionlte),(-selection lte),(-selection-lte)', 'lung', 'check,mate,648', 'pioneer', 'marker ']
exscientia presents novel immuno-oncology biomarker for exs-21546 new data to identify patients that are more likely to respond to its a2ar antagonist, as well as the relationship to potential impact of adenosine on pd-1 inhibitor response.
A Sosei Heptares shareholder.
Practicing English on Twitter